Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma
- 31 August 1989
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 25 (8), 1191-1195
- https://doi.org/10.1016/0277-5379(89)90414-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- 1-hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitroEuropean Journal of Cancer and Clinical Oncology, 1987
- Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutismSurgical Neurology, 1986
- Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogsActa Neuropathologica, 1984
- Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometryJournal of Mass Spectrometry, 1981
- “Organic brain syndrome” secondary to 5-fluorouracil toxicityDiseases of the Colon & Rectum, 1981
- Distribution of 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil by oral administration in mice.Journal of Pharmacobio-Dynamics, 1979
- Plasma amino acid quantitation using gas chromatography chemical ionization mass spectrometry and13C amino acids as internal standardsJournal of Mass Spectrometry, 1978
- Metabolic Fate of 1-Hexylcarbamoyl-5-fluorouracil in RatsXenobiotica, 1978
- Neurotoxicity of Commonly Used Antineoplastic AgentsNew England Journal of Medicine, 1974